Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511244631

Publication Date:

November 4, 2024

Pages:

112

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology by region & country, by Type, and by Application.
The Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology.
麻豆原创 Segmentation
By Company
Abbott Laboratories (Abbott EP)
ABK Biomedical, Inc.
Boston Scientific Corporation
BTG plc
Cook Medical, Inc.
Medtronic, Inc.
Merit Medical Systems, Inc.
Stryker Corporation
TriSalus Life Sciences
Terumo Corporation
Vascular Solutions, Inc.
Segment by Type:
Chemotherapeutic Agent
Radiation Therapy
Drug-eluting Particles
Segment by Application
Hospitals
Specialty Clinics
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Product Introduction
1.2 Global Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology 麻豆原创 Size Forecast
1.3 Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology 麻豆原创 Trends & Drivers
1.3.1 Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Industry Trends
1.3.2 Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology 麻豆原创 Drivers & Opportunity
1.3.3 Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology 麻豆原创 Challenges
1.3.4 Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Players Revenue Ranking (2023)
2.2 Global Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Revenue by Company (2019-2024)
2.3 Key Companies Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Manufacturing Base Distribution and Headquarters
2.4 Key Companies Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Product Offered
2.5 Key Companies Time to Begin Mass Production of Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology
2.6 Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology 麻豆原创 Competitive Analysis
2.6.1 Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Chemotherapeutic Agent
3.1.2 Radiation Therapy
3.1.3 Drug-eluting Particles
3.2 Global Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Type
3.2.1 Global Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value, by Type (2019-2030)
3.2.3 Global Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Specialty Clinics
4.2 Global Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Application
4.2.1 Global Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value, by Application (2019-2030)
4.2.3 Global Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Region
5.1.1 Global Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Region (2019-2024)
5.1.3 Global Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Region (2025-2030)
5.1.4 Global Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value, 2019-2030
5.2.2 North America Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value, 2019-2030
5.3.2 Europe Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value, 2019-2030
5.4.2 Asia Pacific Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value, 2019-2030
5.5.2 South America Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value, 2019-2030
5.6.2 Middle East & Africa Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value
6.3 United States
6.3.1 United States Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value, 2019-2030
6.3.2 United States Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value, 2019-2030
6.4.2 Europe Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value, 2019-2030
6.5.2 China Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Type (%), 2023 VS 2030
6.5.3 China Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value, 2019-2030
6.6.2 Japan Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value, 2019-2030
6.7.2 South Korea Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value, 2019-2030
6.8.2 Southeast Asia Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value, 2019-2030
6.9.2 India Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Type (%), 2023 VS 2030
6.9.3 India Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Abbott Laboratories (Abbott EP)
7.1.1 Abbott Laboratories (Abbott EP) Profile
7.1.2 Abbott Laboratories (Abbott EP) Main Business
7.1.3 Abbott Laboratories (Abbott EP) Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Products, Services and Solutions
7.1.4 Abbott Laboratories (Abbott EP) Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Revenue (US$ Million) & (2019-2024)
7.1.5 Abbott Laboratories (Abbott EP) Recent Developments
7.2 ABK Biomedical, Inc.
7.2.1 ABK Biomedical, Inc. Profile
7.2.2 ABK Biomedical, Inc. Main Business
7.2.3 ABK Biomedical, Inc. Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Products, Services and Solutions
7.2.4 ABK Biomedical, Inc. Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Revenue (US$ Million) & (2019-2024)
7.2.5 ABK Biomedical, Inc. Recent Developments
7.3 Boston Scientific Corporation
7.3.1 Boston Scientific Corporation Profile
7.3.2 Boston Scientific Corporation Main Business
7.3.3 Boston Scientific Corporation Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Products, Services and Solutions
7.3.4 Boston Scientific Corporation Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Revenue (US$ Million) & (2019-2024)
7.3.5 BTG plc Recent Developments
7.4 BTG plc
7.4.1 BTG plc Profile
7.4.2 BTG plc Main Business
7.4.3 BTG plc Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Products, Services and Solutions
7.4.4 BTG plc Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Revenue (US$ Million) & (2019-2024)
7.4.5 BTG plc Recent Developments
7.5 Cook Medical, Inc.
7.5.1 Cook Medical, Inc. Profile
7.5.2 Cook Medical, Inc. Main Business
7.5.3 Cook Medical, Inc. Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Products, Services and Solutions
7.5.4 Cook Medical, Inc. Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Revenue (US$ Million) & (2019-2024)
7.5.5 Cook Medical, Inc. Recent Developments
7.6 Medtronic, Inc.
7.6.1 Medtronic, Inc. Profile
7.6.2 Medtronic, Inc. Main Business
7.6.3 Medtronic, Inc. Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Products, Services and Solutions
7.6.4 Medtronic, Inc. Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Revenue (US$ Million) & (2019-2024)
7.6.5 Medtronic, Inc. Recent Developments
7.7 Merit Medical Systems, Inc.
7.7.1 Merit Medical Systems, Inc. Profile
7.7.2 Merit Medical Systems, Inc. Main Business
7.7.3 Merit Medical Systems, Inc. Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Products, Services and Solutions
7.7.4 Merit Medical Systems, Inc. Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Revenue (US$ Million) & (2019-2024)
7.7.5 Merit Medical Systems, Inc. Recent Developments
7.8 Stryker Corporation
7.8.1 Stryker Corporation Profile
7.8.2 Stryker Corporation Main Business
7.8.3 Stryker Corporation Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Products, Services and Solutions
7.8.4 Stryker Corporation Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Revenue (US$ Million) & (2019-2024)
7.8.5 Stryker Corporation Recent Developments
7.9 TriSalus Life Sciences
7.9.1 TriSalus Life Sciences Profile
7.9.2 TriSalus Life Sciences Main Business
7.9.3 TriSalus Life Sciences Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Products, Services and Solutions
7.9.4 TriSalus Life Sciences Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Revenue (US$ Million) & (2019-2024)
7.9.5 TriSalus Life Sciences Recent Developments
7.10 Terumo Corporation
7.10.1 Terumo Corporation Profile
7.10.2 Terumo Corporation Main Business
7.10.3 Terumo Corporation Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Products, Services and Solutions
7.10.4 Terumo Corporation Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Revenue (US$ Million) & (2019-2024)
7.10.5 Terumo Corporation Recent Developments
7.11 Vascular Solutions, Inc.
7.11.1 Vascular Solutions, Inc. Profile
7.11.2 Vascular Solutions, Inc. Main Business
7.11.3 Vascular Solutions, Inc. Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Products, Services and Solutions
7.11.4 Vascular Solutions, Inc. Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Revenue (US$ Million) & (2019-2024)
7.11.5 Vascular Solutions, Inc. Recent Developments
8 Industry Chain Analysis
8.1 Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Industrial Chain
8.2 Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Sales Model
8.5.2 Sales Channel
8.5.3 Drug Eluting Beads, Microcatheters and Radiopaque Beads in Interventional Oncology Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Abbott Laboratories (Abbott EP)
ABK Biomedical, Inc.
Boston Scientific Corporation
BTG plc
Cook Medical, Inc.
Medtronic, Inc.
Merit Medical Systems, Inc.
Stryker Corporation
TriSalus Life Sciences
Terumo Corporation
Vascular Solutions, Inc.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.